Related Experiment Videos

Gender differences in the primary prevention of stroke with aspirin

Eric E Adelman1, Lynda Lisabeth, Devin L Brown

  • 1Department of Neurology, University of Michigan, Cardiovascular Center, Ann Arbor, MI 48109, USA.

Women'S Health (London, England)
|May 27, 2011
PubMed

Insights

Aspirin may prevent cardiovascular disease, but its effectiveness might differ between men and women. Further research is needed to clarify these potential gender-specific benefits for stroke and heart attack prevention.

Area of Science:

  • Cardiology
  • Neurology
  • Preventive Medicine

Background:

  • Aspirin is widely used for preventing cardiovascular diseases, including ischemic stroke.
  • Primary prevention trials have investigated aspirin's efficacy, but gender-specific data are limited.
  • Previous findings suggested potential gender differences in aspirin's protective effects.

Purpose of the Study:

  • To evaluate the effectiveness of aspirin in the primary prevention of stroke and cardiovascular events.
  • To explore potential gender differences in aspirin's preventive benefits.

Main Methods:

  • Review of seven clinical trials on aspirin for primary prevention.
  • Analysis of data from one meta-analysis.
  • Examination of subgroup data, including gender-specific outcomes.

Main Results:

  • Data suggest aspirin may prevent myocardial infarction in men.
  • Evidence indicates aspirin might prevent stroke in women, though this finding was influenced by a single large study.
  • A subsequent meta-analysis did not confirm a significant gender difference in aspirin's effectiveness.

Conclusions:

  • The potential gender-specific benefits of aspirin for cardiovascular disease prevention require further investigation.
  • Reasons for observed or suggested gender differences in aspirin's efficacy remain unclear.
  • More research is needed to definitively establish aspirin's role in primary prevention across genders.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...